Annual Drug Patent Expirations for STIVARGA
Stivarga is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for STIVARGA.
This drug has two hundred and sixty-two patent family members in fifty-eight countries.
The generic ingredient in STIVARGA is regorafenib. One supplier is listed for this compound. Additional details are available on the regorafenib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
